Baudax Bio, Inc.
490 Lapp Road
Malvern, Pennsylvania 19355
August 24, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549
Attn: Daniel Crawford
| Re: | Baudax Bio, Inc. |
Registration Statement on Form S-1
SEC File No. 333-266499
Request for Acceleration
Mr. Crawford:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Baudax Bio, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-266499), as amended (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 5:15 PM, eastern time, on August 25, 2022, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Hamilton Sanders LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Troutman Pepper Hamilton Sanders LLP, by calling Jennifer Porter at (215) 981-4339.
Please feel free to direct any questions or comments concerning this request to Jennifer Porter, Esq. of Troutman Pepper Hamilton Sanders LLP at (215) 981-4339.
BAUDAX BIO, INC. | ||
| By: | /s/ Gerri Henwood | |
| Name: Gerri Henwood | ||
| Title: President and Chief Executive Officer | ||
Cc: Rachael M. Bushey, Troutman Pepper Hamilton Sanders LLP